Akero Therapeutics Inc 's ROA from the third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Akero Therapeutics Inc 's ROA in the third quarter of 2025?
Akero Therapeutics Inc recorded a cumulative net loss of $-293 million during 12 months ending in the third quarter of 2025, resulting in a negative return on assets (ROA) of -28.58%.

However, within the Healthcare sector 426 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2025 quarter, so far to 3732, from total ROA ranking in the second quarter of 2025 at 3761.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter
Y / Y Total Assets Change	22.88 %	28.36 %	26.7 %	42.13 %	28.68 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-293	-284	-269	-252	-237
Return On Assets (TTM)	-28.58 %	-29.04 %	-29.4 %	-29.46 %	-29.86 %
AKRO's Total Ranking	# 3732	# 3761	# 3838	# 4448	# 3915
Total Assets (TTM) in million	1,006	1,111	1,156	826	819
Seq. Total Assets Change	-9.41 %	-3.92 %	39.91 %	0.9 %	-5.37 %
Seq. Net Income Change	-	-	-	-	-

AKRO's 5 Years Annual ROA >> Back to AKRO Management Effectiveness >> Compare AKRO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 166
Sector	# 427
Overall	# 3691

Return On Assets Statistics
High	Average	Low
-9.53 %	-32.22 %	-56.9 %
(Dec 31 2019)		(Jun 30 2022)

Financial Statements
Akero Therapeutics Inc 's Assets	$ 1,006 million	AKRO's Balance sheet
Akero Therapeutics Inc 's Income	$ -82 million	Quarterly AKRO's Income Statement
AKRO's Income by Division		See AKRO's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	42.13 %	63.18 %	82.16 %	-28.46 %	97.9 %
Total Assets in million	826	581	356	196	273
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-252	-152	-112	-101	-79
Annual Return On Assets	-30.51 %	-26.11 %	-31.45 %	-51.54 %	-28.98 %

AKRO's 5 Years Annual ROA >> Back to AKRO Management Effectiveness >> Compare AKRO ROA to its Competitors

More Return On Assets Ratios
AKRO's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AKRO's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AKRO's Competitors
Subscribers only: Roa for Akero Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for AKRO's Customers

You may also want to know
AKRO's Roi	AKRO's Inventory Turnover Ratio	AKRO's Growth Rates	AKRO's Dividend Comparisons
	AKRO's Profitability Ratios	AKRO's Asset Turnover Ratio	AKRO's Dividend Growth
AKRO's Roe	AKRO's Valuation Ratios	AKRO's Financial Strength Ratios	AKRO's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2025, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:11:34+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.